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Abstract: The enzymes of both de novo and salvage pathways for purine nucleotide synthesis are 
regulated to meet the demand of nucleic acid precursors during proliferation. Among them, the 
salvage pathway enzymes seem to play the key role in replenishing the purine pool in dividing and 
tumour cells that require a greater amount of nucleotides. An imbalance in the purine pools is 
fundamental not only for preventing cell proliferation, but also, in many cases, to promote 
apoptosis. It is known that tumour cells harbour several mutations that might lead to defective 
apoptosis-inducing pathways, and this is probably at the basis of the initial expansion of the 
population of neoplastic cells. Therefore, knowledge of the molecular mechanisms that lead to 
apoptosis of tumoural cells is key to predicting the possible success of a drug treatment and 
planning more effective and focused therapies. In this review, we describe how the modulation of 
enzymes involved in purine metabolism in tumour cells may affect the apoptotic programme. The 
enzymes discussed are: ectosolic and cytosolic 5′-nucleotidases, purine nucleoside phosphorylase, 
adenosine deaminase, hypoxanthine-guanine phosphoribosyltransferase, and inosine-5′-
monophosphate dehydrogenase, as well as recently described enzymes particularly expressed in 
tumour cells, such as deoxynucleoside triphosphate triphosphohydrolase and 7,8-dihydro-8-
oxoguanine triphosphatase. 
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1. Introduction 
Intracellular purine nucleotide concentration is determined and maintained through two 
distinct pathways, both depending on a common metabolite: 5-phosphoribosyl-1-pyrophosphate 
(PRPP) (Figure 1). The de novo pathway consists of 10 reactions catalysed by six enzymes, some of 
which are allosterically regulated mainly by PRPP and purine nucleotides [1]. Furthermore, the six 
enzymes can cluster near mitochondria and microtubules to form dynamic multienzyme complexes 
referred to as “purinosomes” [2]. The purinosome formation causes a strong increase in the rate of 
purine synthesis. This regulatory mechanism ensures that, during proliferation and in the absence of 
preformed purine ring to be salvaged, the supply of purine compounds is secured. When preformed 
purine rings are available, they can be converted in one step into the corresponding nucleoside 
monophosphates through the action of the salvage pathway enzymes adenine 
phosphoribosyltransferase (APRT) and hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
which utilize PRPP as a co-substrate (Figure 1) [1]. The availability of preformed purine ring prevents 
purinosome formation [2]. Regulation both at genetic and protein levels ensures the correct amount 
of nucleotides to sustain replicative and metabolic needs [3]. Therefore, it is not surprising that 
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alterations of replicative rate and eventually activation of apoptosis are a consequence of 
dysfunctions of purine metabolism. Furthermore, an imbalance in purine supply can affect also 
mitochondrial proliferation and function, leading to metabolic changes and apoptosis [4]. 
Nevertheless, in some cases, the relationship between enzyme dysfunction and proliferation rate, 
metabolic alterations, and apoptosis is not as simple and direct as expected. The knowledge of the 
consequences of the alteration of enzymes involved in purine metabolism is essential not only for the 
understanding of “where and how” these enzymes impact metabolic pathways, but also to uncover 
whether they can be targets of antineoplastic drugs or be responsible for drug resistance. This review 
presents the most recent reports on the impact of purine catabolism and salvage enzymes (Figure 2) 
in the activation of apoptosis and the implied molecular mechanisms. Furthermore, the possible 
applications of this knowledge to anti-tumour therapy are discussed. 
 
Figure 1. De novo and salvage pathways for purine nucleotide biosynthesis. Cyan background: de 
novo synthesis; yellow background: salvage synthesis. The figure outlines the central role played by 
PRPP, needed for both de novo and salvage pathways. Hyp: hypoxanthine; Gua: guanine; Ade: 
adenine; Rib-5-P: ribose-5-phosphate; PRPP: 5-phosphoribosyl-1-pyrophosphate; Gln: glutamine; 
Gly: glycine; THF: tetrahydrofolate; Asp: aspartate; S-AMP: succinyl-AMP; XMP: xanthosine-5′-
monophosphate; IMP: inosine-5′-monophosphate; GMP: guanosine-5′-monphosphate; AMP: 
adenosine-5′-monophosphate. 
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Figure 2. Pathways of purine metabolism. 1: Ectosolic 5′-nucleotidase; 2: Adenosine deaminase; 3: 
Cytosolic 5′-nucleotidase II; 4: Purine nucleoside phosphorylase; 5: Hypoxanthine-guanine 
phosphoribosyltransferase; 6: IMP dehydrogenase. Inset: deoxyribonucleoside triphosphates (dNTP) 
are converted into the respective deoxynucleosides (dNs) by a one-step reaction catalysed by a sterile 
alpha motif and histidine-aspartate (HD) domain-containing protein 1 (enzyme 7). An increase in 
reactive oxygen species (ROS) brings about an increase in 8-oxo-dGTP, converted into the 
monophosphate by human MutT homolog 1 (enzyme 8). Ado: adenosine; Guo: guanosine; Ino: 
inosine. 
2. Ectosolic 5′-Nucleotidase 
Ectosolic 5′-nucleotidase (CD73) (EC 3.1.3.5) is a 70-kDa glycosylated protein bound to the outer 
surface of the plasma membrane by a glycosylphosphatidylinositol anchor. The enzyme is 
overexpressed in a variety of tumours [5] and in some of them, is associated with a highly invasive 
cancer phenotype, drug resistance, and tumour-promoting functions [6]. CD73 catalyses the 
dephosphorylation of extracellular AMP to adenosine (Ado), which plays important roles in many 
physiological and pathophysiological conditions through G-protein coupled Ado receptors (A1, 
A2A, A2B, and A3) [7,8]. The roles played by Ado are complex since its interaction with different 
receptors achieves different results; in particular, A1 and A3 receptors are coupled with Gi-proteins 
determining a decrease in cyclic AMP (cAMP), while A2A and A2B receptors are coupled with Gs-
proteins causing an increase in intracellular cAMP [9] (Figure 3). Therefore, the role played by CD73 
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depends on the nature and distribution of the Ado receptors in a particular kind of cell. In addition, 
CD73 plays also many different roles in cell physiology not related to its catalytic activity [10]. 
Analysing enzymatic and non-enzymatic functions of CD73, it was concluded that both faces were 
involved in the aggressive behaviour of cancer cells. The enzymatic function seems to be primarily 
involved in invasion, whereas the non-enzymatic action of the protein contributes to cell adhesion 
and migration through activation of focal adhesion kinase [10]. Among the tumours in which CD73 
is upregulated, breast cancer is the most studied [11]. In some cases of this type of cancer, an 
involvement of CD73 enzymatic activity was demonstrated, since supply of Ado could be a substitute 
for enzyme upregulation in promoting proliferation and motility [12]. In other cases, the involvement 
of different not yet described mechanisms independent of enzyme activity was demonstrated [13]. In 
all cases, an activation of the Akt/GSK-3β pathway was found to be involved in the tumour growth 
and motility promoted by CD73 [13]. In human cervical cancer cells, an increase in cell proliferation 
and motility was associated to CD73 overexpression, but the mechanism was independent of enzyme 
activity. In fact, CD73 inhibitors were unable to prevent the increase in proliferation in cells that 
overexpressed the enzyme. In addition, an increase in Ado, that could be expected when the enzyme 
is overexpressed, induced a decreased cell proliferation [14]. In this type of tumour, an activation of 
the Akt pathway was demonstrated as well [14]. In colorectal cancer, a downregulation of miR-30a 
was shown to determine an increase of CD73 expression in tumour cells, which promoted 
proliferation and inhibited apoptosis. MiR-30a is one of the most important tumour-suppressor 
factors in various human cancers and its level is significantly decreased in several tumours [15]. Since, 
as stated before, many effects exerted by the expression of CD73 on tumours are mediated by the 
participation of the enzyme activity in the conversion of extracellular ATP into Ado, such effects are 
dependent on the amount and nature of the Ado receptors expressed by tumour cells and other cells 
present in the tumour microenvironment. In this regard, in contrast to reports for other cancer types 
(see above), in an in vivo study on medulloblastoma, overexpression of CD73 reduced tumour 
growth and vascularization, and also promoted differentiation and initiated apoptosis, supposedly 
by the accumulation of Ado which interacted with A1 receptor [16]. The level of CD73 expression is 
very important not only for tumour growth and motility, but also for the success of the therapeutic 
approach. In fact, during chemotherapy, various immunogenic mediators accumulate in the tumour 
microenvironment, included ATP. Extracellular ATP, in this case, is released by the cells undergoing 
intrinsically or extrinsically activated apoptosis, through pannexin-1 channels and functions as a 
“find me” signal for P2Y family receptors expressed by macrophages and dendritic cells [17]. In this 
mechanism, the rapid ATP degradation catalysed by several extracellular enzymes is a determinant 
for the immunogenic activation, since the accumulated AMP, which cannot interact with P2Y 
receptors, can generate Ado through CD73, which mainly mediates the immune-escape of tumour 
cells interacting with A2A receptors [18]. Moreover, also in the case of regulatory T-cells (Tregs) in a 
tumour environment, the presence of several signals triggers apoptosis, and apoptotic Treg cells 
achieved superior immuno-suppression via an oxidative stress-associated mechanism [19]. 
Therefore, the induction of apoptosis in a tumour environment in which cells highly expressing CD73 
and Ado receptors A2A are present is not always a successful therapeutic approach. Recently, CD73 
has been targeted for the synthesis of new inhibitory compounds which prevent extracellular Ado 
formation from AMP and the consequent immune-escape [20]. 
3. Cytosolic 5′-Nucleotidase II 
Cytosolic 5′-nucleotidase II (cN-II) (EC 3.1.3.5) is an ubiquitously expressed and highly 
conserved enzyme that hydrolyses purine nucleoside monophosphates (preferentially IMP and 
GMP) into their corresponding nucleosides and inorganic phosphate. Its enzymatic activity and 
biochemical features have been well characterised, and the reader is referred to a recent review for 
further investigation of these issues [21]. The first observation on its prognostic value in nucleoside 
analogue-treated patients with acute myeloid leukaemia indicated that patients with high cN-II 
expression in leukaemic blasts showed a poorer outcome with respect to those with a lower 
expression [22]. Since then, the implication of cN-II in cancer cells and in the response to anticancer 
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treatment has been extensively demonstrated [23,24]. Indeed, shRNA-based cell models with 
downregulated cN-II are more sensitive to purine nucleoside and nucleobase analogues, as compared 
to control cells [25]. The enzyme is highly expressed in tumour cells, and cN-II expression in human 
neuroblastoma cells and in lung cancer cells correlated with cell proliferation [26,27], whereas its 
inhibition in human breast cancer cells was associated with a better defence towards reactive oxygen 
species (ROS) and a better adaptability to glucose deprivation in culture media [28]. In a cell model 
of lung cancer (A549), an activation of p53 and inactivation of Akt following cN-II partial silencing 
was demonstrated [27]. Indeed, in an astrocytoma cell line (ADF), transitory cN-II silencing was 
followed by caspase-3 activation and apoptosis [29]. Furthermore, the siRNA-mediated inhibition of 
cN-II expression in murine skeletal muscles induced an increase in the AMP/ATP ratio and a 
subsequent activation of AMP-activated protein kinase (AMPK) [30], even though this was not 
confirmed in cN-II deficient mice [31]. In parallel to these biological studies, several genetic as well 
as genome wide association studies have identified the cN-II encoding gene NT5C2 or some genetic 
variants as being associated to various pathological conditions such as hereditary spastic paraplegia 
45, psychiatric disorders, a disturbance of blood pressure, and a decrease in body mass index [32]. 
Fluctuation of cN-II expression has been demonstrated to influence the concentration of intracellular 
nucleotides, depending on the type of cell and the technique utilised for enzyme silencing. In some 
cases, the alteration of nucleotide concentration is not statistically significant, but the effect on 
metabolic and proliferative features is still present [27,31,33,34]. These observations indicate that cN-
II regulates several cellular pathways through a mechanism at least partially independent of its 
impact on intracellular nucleotide concentration. 
4. Adenosine Deaminase 
Adenosine deaminase (ADA) (E.C.3.5.4.4) catalyses the deamination of Ado and 
deoxyadenosine (dAdo) to inosine and deoxyinosine, respectively. There are two isoenzymes of ADA 
in human tissues, ADA1 and ADA2 [35]. ADA1 is ubiquitous, has a similar affinity for both 
substrates, and can interact with membrane proteins such as the dipeptidyl dipeptidase-4 (CD26), A1 
[36] and A2A receptors [37]. ADA1 also acts as an ectoenzyme which catalyses the deamination of 
Ado and dAdo in the extracellular space. ADA2 is the main ADA isoenzyme found in human serum 
[35]. Low ADA activity was found in prostate [38] and gastric tumour tissues [39] and in lymphocytes 
of patients suffering from different pathologies, such as gynaecological [40], renal [41], head and neck 
[42], and gastric tumours [43,44], as well as Hodgkin’s lymphoma [45]. Low ADA activity in 
lymphocytes, as outlined later on in this section, could account for the decreased cellular immune 
function in cancer patients. Conversely, ADA activity was increased in cancerous tissue from breast 
[46–48], kidney [49], and colorectal tumours [50], in serum of patients with bladder [51] ovarian [52], 
laryngeal [53], and head and neck squamous cell carcinomas [54,55] and in lymphocytes of patients 
with chronic lymphocytic leukaemia (CLL) [56]. High ADA activity might be advantageous to the 
cancer cells by causing, in association with purine nucleoside phosphorylase (PNP), an increase in 
hypoxanthine, a substrate for the salvage pathway (Figure 2). In addition, increased ADA activity 
might be a compensatory mechanism against toxic accumulation of its substrates. Indeed, Ado and 
dAdo are known to induce apoptosis, and ADA inhibition is an antitumoural strategy. Insights from 
the apoptosis-induced effect of ADA deficiency were obtained from studies regarding severe 
combined immunodeficiency (SCID) caused by mutations in the ADA1 gene. The primary cause of 
lymphotoxicity in ADA-SCID is considered to be the accumulation of dAdo and dATP. In the absence 
of ADA activity, Ado and dAdo accumulate both in the extracellular compartments and inside the 
cells. dAdo is then phosphorylated by deoxycytidine kinase (dCK) and/or ADK to dAdo 
monophosphate, which in turn is converted to dAdo triphosphate (dATP). Intracellular dATP might 
generate DNA strand breaks and inhibit ribonucleotide reductase, leading to DNA synthesis 
impairment and apoptosis [57]. Deoxycoformycin (dCF), a powerful inhibitor of ADA [58], has been 
used alone or in combination with other drugs for the treatment of several types of lymphatic 
leukaemia [59–62]. dATP accumulation induced by dCF in hairy cell leukaemia led to activation of 
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p53, release of cytochrome c from mitochondria and activation of apoptotic protease-activating factor 
1 (Apaf-1), and therefore caspase-9 and caspase-3 activation [63]. 
The combination of dAdo and dCF was found to be toxic for several tumoural cell lines such as 
rat hepatoma cells [64], and human colon carcinoma cell lines LoVo and HT29 [65–67]. The treatment 
with dAdo and dCF in combination resulted in the activation of the apoptotic mitochondrial pathway 
in LoVo, human astrocytoma, and neuroblastoma cell lines [67–70] with cytochrome c release and 
caspase-3 activation. Activation of caspase-8, and of both caspase-9 and -8 has also been found in 
astrocytoma and in neuroblastoma cells, respectively [69,70]. In astrocytoma cells, but not in 
neuroblastoma cells, a reduction in the production of lactate preceded the effect of dAdo and dCF on 
cell viability, suggesting a decreased glycolytic capacity. In both cell lines, dAdo must be 
phosphorylated in order to exert its cytotoxic effect; however, a decrease in the energy charge was 
observed in astrocytoma, but not in neuroblastoma cells [69,70]. 
 
Figure 3. Effectors of adenosine receptor-mediated apoptosis. The figure shows the different types of 
G-proteins associated with the four adenosine receptors and illustrates the apoptosis effectors found 
in several models by using agonists and antagonists of the receptors, or receptor silencing. The 
numbers in brackets refer to the respective reference. Note that adenosine receptors can be involved 
in survival in other cell types [71]. 
The involvement of the four Ado receptors in apoptosis of cancer cells has been reported and 
reviewed recently [71,72]. Apoptosis can occur through A1 [73–75], A2A [76–78], A2B [79,80], and A3 
[81–89] receptors (Figure 3). Extracellular Ado can enter the cells through Ado transporters, and as 
intracellular Ado is converted by ADK to AMP which can activate AMPK, an energy sensor of the 
cells involved both in survival and cancer suppression (for a recent review see [90]). AMPK is 
responsible for apoptosis in some human gastric [91,92] cancer cells and astrocytoma cells among 
others [74]. In human mesothelioma cells this pathway led to upregulation of p53 [93]. p53 exerts its 
pro-apoptotic effect by transcription-dependent and transcription-independent actions. The targets 
of p53 transactivation are pro-apoptotic members of the Bcl-2 family (Bax, Bid, Puma, Noxa), as well 
as other apoptotic effector proteins (Apaf-1, caspase-8, caspase-6), cell death receptors, and cell death 
ligands. The p53 protein also acts directly in the mitochondria facilitating the oligomerization of Bax 
and Bak and interacting with anti-apoptotic Bcl-2, Bcl-xL, and Mcl-1 proteins [94]. The ADA inhibitor 
erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) but not dCF, induced apoptosis in malignant pleural 
mesothelioma [95] by increasing intracellular Ado that needed to be converted to AMP, since ADK 
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inhibition neutralised the effect. EHNA also inhibits cyclic nucleotide phosphodiesterase [96], 
therefore, it was postulated that this enzyme might have a role in the cytotoxicity observed in these 
cells. In addition, Ado-induced apoptosis involves the intrinsic and extrinsic pathways resulting in 
caspase-3 activation, and caspase-independent pathways leading to accumulation of Apoptosis 
Inducing Factor (AIF) (or its homologous AIF-homologous mitochondrion-associated inducer of 
death, AMID) in the nucleus [71,97]. AIF can be released from mitochondria, migrates to the nucleus 
where it can recruit nucleases, or organize a DNA-degrading complex [98]. In human hepatoma cells, 
Ado upregulated AMID, and promoted its translocation to the nucleus where it may induce DNA 
degradation [99]. Ado accumulation also reverses the action of S-adenosylhomocysteine hydrolase, 
increasing S-adenosylhomocysteine, which inhibits the transmethylation reactions. S-
adenosylhomocysteine has been suggested to be involved in Ado-induced apoptosis in hepatoma 
HepG2 by altering gene expression [100]. It is interesting to note that dCF, through Ado receptor-
dependent mechanisms, was also able to decrease the aggressiveness of cancer cells by modulating 
migration and invasion and by regulating endothelial cell permeability [101]. 
5. Purine Nucleoside Phosphorylase 
Human purine nucleoside phosphorylase (hPNP) (EC 2.4.2.1), an ubiquitously expressed 
homotrimer, catalyses the phosphorolysis of 6-oxo-ribo- and 6-oxo-2′-deoxyribo-nucleosides to the 
corresponding bases and pentose-1-phosphate, but does not accept Ado and dAdo as substrates [102]. 
Conversely, the homoexameric Escherichia coli PNP (ePNP) efficiently acts on adenine-based 
nucleosides [103]. 
The importance of hPNP for T-cell functions was recognised more than 40 years ago [104] with 
the discovery that an inherited deficiency of this enzyme caused a severe T-cell lymphopaenia. In 
fact, the inhibition of PNP allows for the phosphorylation of 6-oxo-2′deoxyribo-nucleosides which 
are channelled towards nucleotide synthesis instead of degradation. In particular, T-cell specific 
toxicity results from the inherently high phosphorylation of dGuo and the slow catabolism of dGMP 
in this cell type [105,106]. The major kinase activities responsible for the phosphorylation of dGuo 
appear to be cytosolic dCK and mitochondrial deoxyguanosine kinase [106]. dGMP is then converted 
to dGTP in two non-rate limiting kinase reactions. The overproduction of dGTP perturbs the 
deoxyribonucleotide pool, inhibits DNA synthesis, and induces cell death through mechanisms that 
will be discussed later on in this section. These observations provided a rationale for the development 
of hPNP inhibitors for the treatment of leukaemia. Among these inhibitors, forodesine (also known 
as immucillin H), a transition state analogue inhibitor of hPNP [107], has been thoroughly 
investigated as antineoplastic agent, in particular against T-cell mediated disorders. In PNP-deficient 
mice the mitochondrial deoxyguanosine kinase activity appears to be the responsible for the 
accumulation of dGTP in mitochondria, which leads to cell death with mitochondrial damage [108]. 
This abnormal accumulation interferes with mitochondrial DNA synthesis and repair [109], leading 
to p53 activation and apoptosis [110,111], possibly related to forodesine-induced ROS production and 
loss of mitochondrial membrane potential [112]. In vitro experiments performed with cultured 
human leukaemia cells demonstrated the toxicity of the combination of forodesine and dGuo 
[113,114]. In CLL, results indicate that forodesine induces apoptosis both through a p53-dependent 
[113] and a p53-independent [112] pathway. Balakrishnan et al. [113] reported studies carried out in 
leukaemic lymphocytes obtained from patients with CLL. The treatment with dGuo and forodesine 
in combination led to an increase in dGTP content, which correlated with a stabilization through 
Ser15 phosphorylation of p53, with an upregulation of downstream protein p21. A correlation 
between dGTP accumulation and caspase-8, -9, and -3 activation and subsequent polyADP-ribose 
polymerase (PARP) cleavage was also observed. Furthermore, all these effects appeared to be 
tumour-specific, as normal T and B lymphocytes isolated from healthy subjects did not undergo 
apoptosis. Alonso et al. [112] showed that forodesine in combination with dGuo induced a dose-
dependent cell death in CLL cells, but the response was independent of deletions in 17p13 (TP53) and 
11q22-q23 (ATM), genetic aberrations acquired in advanced disease and associated with drug 
resistance and short survival [115]. Therefore, forodesine activated the mitochondrial apoptotic 
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pathway, acting by a p53-independent mechanism in tumours with no functional p53. Interestingly, 
the authors found an upregulation of the p53 homolog p73 at transcriptional and translational level 
in CLL cells with p53 deletion, thus suggesting that this antileukaemic agent might be beneficial in 
CLL patients with impaired p53-dependent apoptotic pathway [115]. For the clinical practice of 
forodesine against lymphoblastic leukaemia, the reader is referred to previously published reviews 
and articles [116–118]. 
Gene-directed enzyme prodrug therapy (GDEPT) is a strategy of prodrug delivery which 
comprises a three component-system: an inactive drug (prodrug), a gene coding for the enzyme that 
converts the inactive prodrug into the active drug, and a vector [119]. For the choice of the vector and 
the specific gene delivery to the target tumour cell, the reader is referred to previously published 
reports [119,120]. In the early 1990s Parker et al. developed a gene therapy strategy based on the 
selective expression of the ePNP gene in tumour cells [121,122]. The bacterial enzyme, unlike 
mammalian PNP, can accept Ado and its analogues as substrates [103] and can be used to cleave 
nontoxic purine nucleoside analogues to very cytotoxic adenine analogues [122]. The toxic purine 
base analogues generated by ePNP readily diffuse across cell membrane, therefore killing not only 
the tumour cell in which they are generated, but also many surrounding tumour cells that do not 
express ePNP (bystander effect). The first prodrug used with ePNP was 9-β-D-[2-
deoxyribofuranosyl]-6-methylpurine (MeP-dR), which, being a poor substrate for human salvage 
enzymes, such as dCK and hPNP, is not cytotoxic to human cells [123]. Therefore, its toxicity is 
exerted in tumour cells, where ePNP GDEPT is directed: in fact, 6-methylpurine (MeP), the product 
of MeP-dR phosphorolysis, is activated to the cytotoxic compound by cellular HPRT and/or APRT 
activities (see Section 6) and then incorporated both in RNA and DNA. Two other dAdo analogues, 
2-fluoro-2′-deoxyadenosine (F-dAdo) and 9-β-arabinofuranosyl-2-fluoroadenine (F-araAde), have 
also received attention as substrates of ePNP. They are transformed by ePNP to 2-fluoroadenine (F-
Ade), an adenine analogue approximately 100-fold more potent than MeP [122], which is converted 
to the cytotoxic mononucleotide by APRT. With F-araAde being an insoluble compound, it is 
administered as F-araAde-5′-monophosphate (F-araAMP), which must be dephosphorylated by 
plasma phosphatases, before entering the cell (Figure 4). An important feature of the ePNP GDEPT 
is its inhibition of protein and RNA/DNA synthesis, making it a good therapeutic approach for solid 
tumours, which exhibit a high fraction of non-replicating cells [123–125]. The ePNP/F-araAMP 
GDEPT in combination with docetaxel was used against multidrug-resistant ovarian cancer cells 
[126] and castration-resistant prostate cancer cells [127]. In both cases the involvement of apoptosis 
in tumour cell death was established. In particular, in ovarian cancer cells, a down-regulation of anti-
apoptotic Bcl-2 protein and upregulation of pro-apoptotic Bax, Bik, and Bok proteins were achieved 
with the treatment. Furthermore, a caspase-mediated proteolysis of PARP was observed [126]. 
Krohne et al. [128] demonstrated that ePNP/F-araAMP induced hepatocellular carcinoma cell death 
predominantly by apoptosis, which occurred earlier in p53-positive HepG2 cells, as compared to p53-
negative Hep3B cells. However, the efficiency of tumour cell death was similar in both cell lines. 
Moreover, they also demonstrated that the induction of apoptosis was independent of the Fas/FasL 
signalling pathway. They concluded that the ePNP GDEPT could be advantageous against tumours 
carrying p53 mutations or resistant to Fas-mediated apoptosis [128]. 
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Figure 4. Metabolism of F-araAMP in normal and tumoural cells subjected to Escherichia coli PNP 
(ePNP)/F-araAMP GDEPT. 9-β-arabinofuranosyl-2-fluoroadenosine 5’-monophoaphate (F-araAMP) 
is cleaved by plasma phosphatases into 9-β-arabinofuranosyl-2-fluoroadenine (F-araAde), which 
enters both normal and tumoural cells. Inside the cell, it is activated to the monophosphate by cellular 
deoxycytidine kinase (dCK). In tumour cells, the presence of ePNP allows for an additional activation 
pathway, which proceeds through a phosphorolytic cleavage to give 2-fluoroadenine (F-Ade), which 
is activated by cellular adenine phosphoribosyltransferase (APRT). Through the action of 
ribonucleotide reductase (RR), F-ADP is converted to the respective deoxynucleotide, thus interfering 
also on DNA synthesis. GDEPT: gene-directed enzyme prodrug therapy. 
6. Hypoxanthine Guanine Phosphoribosyltransferase 
HPRT (EC 2.4.2.8) plays a central role in the purine salvage pathway. The enzyme catalyses the 
conversion of guanine and hypoxanthine to the respective nucleoside monophosphates, by using 
PRPP as donor of the phosphoribosyl moiety [129]. Adenine is not a substrate of the enzyme; indeed, 
for the salvage of this purine base, an additional APRT activity (EC 2.4.2.7) is required [130]. The 
relevance of HPRT in the process of activation of thiopurines for the treatment of malignancies, 
rheumatic diseases, inflammatory bowel disease, and other pathologies is well documented [131,132]. 
In fact, HPRT catalyses the conversion of 6-thioguanine to 6-thioguanosine monophosphate and 
represents the first step towards the production of deoxy-6-thioguanosine 5′-triphosphate. This 
modified deoxynucleoside triphosphate is incorporated into DNA and is further methylated by S-
adenosylmethionine to form S6-methylthioguanine, which, during DNA replication, pairs with 
thymine and its normal partner, cytosine [133]. The mispairs induced by 6-thioguanine are processed 
by the DNA mismatch repair leading to cell-cycle arrest followed by apoptosis [133,134]. In colorectal 
cancer cell lines proficient in mismatch repair, an interconnection between autophagy and apoptosis 
has been demonstrated. In fact, thiopurines induced autophagy as a survival mechanism which 
antagonises apoptosis. On the other hand, apoptosis was the major cell death mechanism, since 
caspase inhibition protected the cells from death induced by thiopurines. Interestingly, the inhibition 
of apoptosis promoted autophagic response [135]. Thus, a tight interplay between apoptosis and 
autophagy controls cell fate in response to thiopurines. In fact, thiopurines induced mitochondrial 
depolarization and increased ROS production, which activated mitophagy for the degradation of 
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damaged mitochondria. However, when mitochondrial depolarization exceeded the threshold for 
the activation of the cell death machinery, cells were directed to apoptotic death [135]. Therefore, ROS 
play a relevant role in thiopurine-induced cell death and represent a critical factor that links 
autophagy and apoptosis through mitochondria. 
7. Inosine 5′-Monophosphate Dehydrogenase 
Inosine 5′-monophosphate dehydrogenase (IMPDH) (EC 1.1.1.205) is a cytoplasmic enzyme that 
catalyses the NAD-dependent oxidation of inosine monophosphate (IMP) to xanthosine 
monophosphate (XMP), the first and rate-limiting step toward the de novo synthesis of GTP [136]. 
This enzyme plays a central role in purine metabolism, since guanylates are needed not only for 
nucleic acid synthesis, but also for cellular regulation, such as signal transduction, energy transfer, 
and microtubule dynamic instability [137]. Two isoforms of IMPDH have been identified: type 1 and 
type 2 [138]. Human IMPDH type 1 (hIMPDH1) is ubiquitously expressed and its activity is 
maintained at near constant level in normal and neoplastic cells, whereas the human IMPDH type 2 
(hIMPDH2) isoform appears upregulated in proliferating cells [139]. The disproportionate increase 
of hIMPDH2 activity in neoplastic cells has made this isoform a key target for the development of 
anticancer drugs. The underlying rationale for the increased activity of hIMPDH2 may be that, 
although guanylates can be salvaged from guanine by HPRT, the level of circulating guanine is low 
in dividing cells and this route is probably insufficient to satisfy the needs of guanylates. Indeed, both 
natural and synthetic inhibitors of IMPDH are used as anticancer [139], antiviral [140], 
immunosuppressive, and antimicrobial agents [141–146]. In Tuberous Sclerosis Complex 2 (TSC-2) 
deficient cell and tumour models with aberrantly elevated mammalian Target of Rapamycin 
Complex 1 (mTORC1) signalling and actively producing ribosomes, IMPDH inhibition, by limiting 
the nucleotide pool, leads to selective replication stress, DNA damage, and apoptosis [147]. 
Moreover, a selective vulnerability to IMPDH inhibition was reported in a subset of small cell lung 
cancers, expressing high level of MYC, a transcription factor which appears to regulate purine 
biosynthesis by activating transcription of IMPDH [148]. Recently, it was found that un upregulation 
of IMPDH2 drives GTP biosynthesis, enhances rRNA and tRNA synthesis, and stimulates nucleolar 
hypertrophy in glioblastoma cells, thus connecting these features of malignant transformation [149]. 
Several research groups reported the non-enzymatic functions of IMPDH; IMPDH binds to DNA and 
RNA in vivo, in a manner independent of its catalytic activity [150]. Indeed, IMPDH was found in the 
nuclei of human cells, and several experiments suggest that IMPDH has a role in replication, 
transcription and translation. For example, IMPDH interacts with polyribosomes through a 
subdomain and is associated with translating rhodopsin mRNA [151]. Moreover, the evidence that 
recruitment of IMPDH to actively transcribed genes mediates C-terminal domain phosphorylation of 
RNA polymerase II in yeast supported a new cellular function of IMPDH [152]. IMPDH also acts as 
a cell- cycle-regulated transcription repressor. At the end of S-phase, the enzyme accumulates in the 
nucleus and represses proliferation genes such as those coding histones and E2f, a master driver of 
the G1/S transition [153]. In human embryonic kidney HEK293 and human colon cancer HCT116 
cells, p53 regulated purine metabolism through a p53-miR-34a-IMPDH pathway (miR-34a is a master 
regulator of tumour suppression) and consequently, miR-34a-mediated inhibition of IMPDH 
perturbed the GTP-dependent Ras signalling pathway [137]. Inhibition of IMPDH activity has also 
been shown to induce differentiation in some cancer cell lines [154–157], while apoptosis was induced 
in other cell lines [158–161]. Over the past 30 years, several IMPDH inhibitors have been tested on 
many cancer models. Apoptosis triggered by these inhibitors occurs through multiple pathways 
depending on the type of compound and the used tumoural model. Figure 5 summarizes the 
apoptotic pathways triggered by the best known IMPDH inhibitors [136,137,162–170]. In all the 
experiments, apoptotic mechanisms were reversed by the simultaneous addition of guanosine, that, 
through the salvage pathway, circumvents the IMPDH inhibition by restoration of the guanylate 
pool. 
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Figure 5. Apoptotic pathways triggered by inosine 5′-monophosphate dehydrogenase (IMPDH) 
inhibitors. The decrease in guanylate pool can trigger apoptosis through multiple pathways: (1): 
downregulation of the MEK/ERK pathway with inhibition of Bcl-2 and activation of Bax and 
cytochrome c release [167]; (2): downregulation of Src/PI3K pathway with inhibition of Akt, with 
downregulation of mammalian target of rapamycin (mTOR) and activation of pro-apoptotic Bak and 
Bax with Apoptosis Inducing Factor (AIF) and endonuclease G (Endo G) release from mitochondria 
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(caspase-independent apoptosis) [136,162,163]; (3): upregulation of p53 with (a) downregulation of 
Bcl-2 and Bcl-xL, with consequent inhibition of p27 and survivin, cytochrome c (Cyt c) release, and 
activation of caspase-9, caspase-3 and polyADP-ribose polymerase (PARP; intrinsic apoptotic 
pathway) [159–161,164,165], (b) upregulation of PUMA and BIM with consequent SMAC/DIABLO 
release from mitochondria, inhibition of Inhibitor of Apoptosis (IAPs) (a caspase-3 inhibitor) with 
activation of caspase-3 [164], and (c) activation of caspase-2 with cleavage of Bid into truncated Bid 
(t-Bid) and AIF/Endo G release from mitochondria [164]; (4): synergistic effect of IMPDH inhibitors 
with TRAIL through binding with death receptors (DR4 and DR5) which recruit initiator caspase-8 
via the adaptor protein FADD. Activated caspase-8 stimulates apoptosis via two parallel cascades: 
direct cleavage and activation of caspase-3, or cleavage of Bid into t-Bid which translocates to 
mitochondria, inducing cytochrome c release, with sequential activation of caspase-9 and -3 (extrinsic 
apoptotic pathway) [164]. TRAIL: tumour necrosis factor-related apoptosis-inducing ligand; FADD: 
Fas-associated protein with death domain. 
8. Sterile Alpha Motif and HD Domain-Containing Protein 1 
Sterile alpha motif and HD domain-containing protein 1 (SAMHD1) was identified as a 
mammalian deoxynucleoside triphosphate triphosphohydrolase (dNTPase, EC 3.1.5.-), which plays 
a key role in the regulation of dNTP homeostasis through hydrolysis of intracellular dNTPs to give a 
free deoxynucleoside and a triphosphate [171,172]. SAMHD1 has been also identified as an important 
host restriction factor that inhibits the infection of several retroviruses and DNA viruses by 
diminishing the intracellular dNTP pool needed for their replication [173]. SAMHD1 has also been 
implicated in the regulation of immune responses [174]. Homozygous mutations in SAMHD1 gene 
have been identified in 17% of patients with Aicardi-Goutières syndrome (AGS), an autoimmune 
disorder that is attributed to excessive accumulation of small DNA fragments in brain. Additionally, 
homozygous deletion in the SAMHD1 gene was also identified in atypical AGS patients [175]. 
SAMHD1 somatic mutations have been identified in several cancers, including solid cancers such as 
glioblastoma [176], colorectal [177], lung [178], and pancreatic cancers [179] and blood-related 
malignancies such as CLL [180] and myeloma [181]. Additionally, SAMHD1 mRNA and/or protein 
expression is also significantly downregulated in CLL [180] and breast [182] and lung cancers [183]. 
Crystallographic studies have demonstrated that SAMHD1 is a homotetrameric enzyme allosterically 
activated by dNTPs [184]. Each monomer contains one catalytic site specific for dNTPs and two 
allosteric sites: site one has a very high affinity for GTP and dGTP and site two is specific for 
deoxyribose and binds all four dNTPs with lower affinity than site one [185]. The active site of 
SAMHD1 can accommodate various base modifications, indeed, SAMHD1 hydrolyses 2-amino-2′-
dATP, O6-methyl-dGTP, 5-methyl-2′-dCTP and 2-thio-dTTP as well as the canonical substrates, 
suggesting a role of the enzyme in the metabolism of nucleoside analogues of therapeutic interest 
[186]. Furthermore, monomeric and dimeric SAMHD1 bind to single-stranded nucleic acids [187,188], 
while the tetrameric form of the enzyme is active as a dNTPase [188]. On this basis, Seamon et al. 
[188] proposed a model in which the level of cellular dNTPs operates as a switch between the two 
types of SAMHD1 activity. Under conditions of low dNTP concentrations, the monomeric and 
dimeric forms would prevail, with high affinity for single-stranded RNA, whereas when dNTP 
concentrations are high, the tetrameric dNTPase would be predominant. These observations suggest 
that the single-stranded nucleic acid binding activity of SAMHD1, in addition to its dNTPase action, 
are likely determinants involved in retrovirus restriction and immune activation. Recent progress 
indicates that gene mutations and epigenetic mechanisms lead to downregulation of SAMHD1 
activity or expression in multiple cancers. Impaired SAMHD1 function can cause increased dNTP 
pool resulting in genomic instability and cell-cycle progression, thereby facilitating cancer cell 
proliferation [189]. In line with this conclusion, exogenous expression of SAMHD1 inhibited 
proliferation and induced apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells, through 
increased activation of extrinsic apoptotic signalling mediators, and sensitised the cells to FasL-
stimulated apoptosis [190]. In addition, in an acute myeloid leukaemia-derived human leukaemic cell 
line (THP I), SAMHD1 knockout induced cell proliferation and reduced apoptosis and this effect was 
in part due to activation of PI3K-Akt-p27 signalling axis. Furthermore, the SAMHD1 knockout 
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attenuated the ability of THP-1 cells to form subcutaneous tumour cells in xenografted 
immunodeficient mice. This effect correlated with significantly increased expression of tumour 
necrosis factor α (TNF-α) in cancer, which may suggest that TNF-α-mediated inflammation could 
account for the decreased tumourigenicity in vivo [191]. 
9. Human MutT Homolog 1 
Human MutT homolog 1 (MTH1) is a widely expressed monomeric enzyme that hydrolyses 
oxidised purine nucleoside triphosphates, such as 8-oxo-dGTP, 8-oxo-dATP and 2-hydroxy-dATP, to 
monophosphates and pyrophosphate (7,8-dihydro-8-oxoguanine triphosphatase, EC 3.6.1.55) [192]. 
It is mostly present in cytosol and, in lesser amounts, in mitochondria and in nuclei. Higher 
expression levels of the enzyme were found in thymus, testis, embryo, proliferating blood 
lymphocytes [193], and in cancer cells when compared with normal ones [194]. Its enzymatic activity, 
together with its cellular distribution and the overexpression in cancers, lead to hypothesise for 
MTH1 a possible role in the sanitization of nucleotide pools both for nuclear and mitochondrial 
DNA/RNA replication and transcription processes, preventing the misincorporation of oxidised 
nucleotides into nucleic acids (Figure 6, Panel 1). In fact, cancer cells are characterised by a marked 
alteration of the redox status with a consequent increase in ROS [195]. A small increase in ROS levels 
promotes proliferation and cancer cell survival [196,197], whereas large amounts of ROS inhibit 
proliferation [198] and promote senescence [199,200] and apoptosis in several cancer models [200–
203]. While it is widely accepted that MTH1 is dispensable in healthy cells [194], the role of the 
enzyme in removing oxidised dNTP in cancer cells, thus promoting their survival, and the 
consequent possibility to use this enzyme as a chemotherapeutic target, is controversial. These 
discordances, arising probably from the use in the different reports of different experimental 
conditions (inhibitors, siRNA, shRNA, or CRISPR technique) and models (cell cultures, xenograft, 
etc.), have been reviewed in the past few years and the reader is referred to these extensive reviews 
for a close examination [194,204–206]. We will focus on the mechanisms by which targeting MTH1 
could lead, according to the supporters of this thesis, to apoptosis and/or senescence of cancer cells. 
Downregulation or inhibition of MTH1 leads to the incorporation in nuclear and mitochondrial DNA 
of oxidised nucleotides (Figure 6, Panel 2), which may be removed by a base excision repair (BER) 
process [194,207]. It has been proposed that wild type p53 is able to stimulate the BER response at 
different levels [208–210]. However, the excessive incorporation in DNA of oxidised nucleotides, may 
cause an overload of the finely coordinated BER system, leading eventually to the production of 
either abasic sites or single strand brakes or double strand brakes [194]. A connection between this 
DNA damage and different detrimental effects (stop of cell cycle in G1, senescence, apoptosis p53, 
caspase-3 mediated or parthanatos) has been proposed [111,194,200,206,211] (Figure 6, panel 2a). 
Conversely, if the BER process does not work properly, or in models containing null or mutant p53 
[212,213], tumourigenesis can be promoted via the accumulation of mutations caused by the 
mispairing of 8-oxo-dGTP and 2-hydroxy-dATP (Figure 6, Panel 2b). In addition, 8-oxo-dGTP 
promotes chain termination following insertion by telomerase into the repeated telomeric sequence 
TTAGGG [214], and in oxidant conditions, cancer cells with very short telomers are quite sensitive to 
MTH1 downregulation [214] (Figure 6, Panel 2c). 
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Figure 6. Scheme of possible effects of therapeutic use of human MutT homolog 1 (MTH1). Panel 1: 
Cancer cell proliferation is stimulated by the accumulation of ROS, which favours the formation of 8-
oxo-dGTP and 2-hydroxy-dATP. In order to avoid the potentially toxic effects of the incorporation of 
oxo-derivatives of nucleotides, the cells upregulate MTH1 sanitizing enzyme. Panel 2: 
downregulation or inhibition of MTH1 leads to an abnormal incorporation of oxidised nucleotides in 
DNA. Panel 2a: in order to deal with this excessive accumulation of oxo-nucleotides in DNA, the base 
excision repair (BER) system is, in general, upregulated. If the misincorporation of oxo-nucleotides 
exceeds the capability of BER, abasic sites (AS) or single strand brakes (SSB) or double strand brakes 
(DSB) accumulate, leading to several serious consequences. Panel 2b: if BER is downregulated, 
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incorporated oxo-nucleotides are not repaired. In this case no cytotoxic effect is reported, but a 
promotion of tumourigenesis can occur. Panel 2c: the misincorporation of 8-oxo-dGTP by telomerase 
into the repeated telomeric sequence TTAGGG leads to the inhibition of the polymerase activity of 
the enzyme. 
10. Concluding Remarks 
A correct balance of NTPs and dNTPs is necessary for the prevention of multiple pathologies. A 
healthy cell must maintain two asymmetric and spatial-temporal dNTP pools; one for nuclear DNA 
(nDNA) synthesis and repair and another for mitochondrial DNA (mDNA) replication and repair. 
Disruptions in dNTP balance are associated with enhanced mutagenesis, leading to genomic 
instability which promotes cancer [215] and may have a role in metabolic disease [216]. Cytosolic 
dNTP pool concentrations positively correlate with the cell cycle. In fact, the quantity of dNTPs at 
the beginning of S-phase is not sufficient for a complete DNA duplication [217]. The increase of 
dNTPs during the S-phase is necessary for faithful nDNA replication. mDNA is replicated 
continuously in post-mitotic cells, and faithful maintenance of mDNA also depends on correctly 
balanced dNTPs [218]. Thus, both proliferating and non-proliferating cells need to fine-tune 
nucleotide and dNTP synthesis to allow for both nDNA and mDNA replication and repair to 
maintain the health of the cell. Indeed, starvation or mTORC1 inhibition leads to selective autophagy 
of ribosomes, providing a source of nucleosides to be used by the salvage pathway enzymes for the 
synthesis of nucleotides, thus contributing to starved cell survival [219]. An imbalance of NTPs may 
have metabolic consequences and also generate an imbalance of dNTPs that can be synthesised by 
salvage of deoxynucleosides and by NDP reduction catalysed by ribonucleotide reductase. A 
plethora of signals concur to activate DNA repair mechanisms or to promote apoptosis in cells in 
which NTP pools are altered. The knowledge of the pathways linking enzyme expression or 
inhibition and apoptosis is fundamental to find new chemotherapeutic approaches able to activate 
apoptosis in cancer cells. Enzyme inhibition or silencing techniques were utilised to demonstrate the 
involvement of several interconverting or salvage enzymes in the determination of nucleotide 
imbalance. Some enzymes described in this review have been demonstrated or suspected to also have 
a role distinct from catalytic activity. In fact, ectosolic 5′-nucleotidase promotes cancer not only 
through the production of ectosolic Ado: cytosolic 5′-nucleotidase regulates proliferation and 
apoptosis in a way not so easily attributable to its regulation of intracellular nucleotide concentration, 
IMPDH also acts as transcription factor, and, finally, SAMHD1 binds to single-stranded RNA. All 
these observations make it difficult to directly link enzyme dysfunction with NTP imbalance and 
activation of apoptosis. Unfortunately, in many papers the nucleotide imbalance was inferred by the 
alteration of enzyme expression or inhibition and the consequent activation of the apoptotic 
programme, while the effective nucleotide concentration was not measured. Furthermore, in the case 
of enzymes involved in the Ado metabolism it is not so easy to distinguish between the effects exerted 
by Ado itself and those mediated by the interaction with its receptors. In addition, dAdo that does 
not interact with Ado receptors is able to trigger apoptosis through the formation of dATP and 
possibly through other still unknown mechanisms. In any case, the knowledge of the catalytic 
capacity of the enzymes involved in the pathways of Figure 2 and of their substrate specificity and 
regulation opened the way to novel pharmacological approaches to cancer therapy. Furthermore, the 
sometimes-surprising results obtained by their inhibition or silencing indicate that much more needs 
to be unravelled about purine salvage and interconverting pathways. 
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